menu
    • menu
    [{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OQL025","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Polymed Biopharmaceuticals","sponsor":"Photys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2025","type":"Licensing Agreement","leadProduct":"PHT-776","moa":"IRAK4","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Polymed Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Polymed Biopharmaceuticals \/ Photys Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Polymed Biopharmaceuticals \/ Photys Therapeutics"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OQL036","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Diacerein","moa":"TYK2\/JAK1","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accro Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Accro Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FZ007-119","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Fermion Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Guangzhou Fermion Technology \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC50","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ascletis Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Ascletis Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASC50

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ascletis’ IL-17 Inhibitor ASC50 IND Cleared by FDA for Psoriasis Study

                            Details : ASC50 is an oral small molecule inhibitor of IL-17, an important biologically and commercially validated target for multiple autoimmune and inflammatory diseases, including psoriasis.

                            Product Name : ASC50

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2025

                            Lead Product(s) : ASC50

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polymed Biopharmaceuticals

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Polymed Biopharmaceuticals

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHT-776

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Photys Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Photys, Polymed Sign Exclusive Deal for Phase 1-Ready IRAK4 Degrader Development

                            Details : Under the agreement, Polymed has granted Photys an exclusive global license to develop, and commercialize HPB-143 (PHT-776) for treating atopic dermatitis.

                            Product Name : HPB-143

                            Product Type : PROTACs

                            Upfront Cash : Undisclosed

                            February 20, 2025

                            Lead Product(s) : PHT-776

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Photys Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Guangzhou Fermion Technology

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Guangzhou Fermion Technology

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FZ007-119

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

                            Details : FZ007-119 is a third-generation JAK inhibitor targeting TYK2 JH2. It's IND application is approved after preclinical studies for plaque psoriasis, inflammatory bowel disease & rheumatoid arthritis

                            Product Name : FZ007-119

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 02, 2024

                            Lead Product(s) : FZ007-119

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OnQuality Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            OnQuality Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OQL025

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OnQuality Gets FDA Clearance for IND Application Of OQL025 for Acneiform Rash

                            Details : OQL025 is a first-in disease topical agent to treat moderate to severe acneiform rash in patients receiving EGFR inhibitors.

                            Product Name : OQL025

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 01, 2024

                            Lead Product(s) : OQL025

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Accro Bioscience

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Accro Bioscience

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diacerein

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permissio...

                            Details : AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.

                            Product Name : AC-201

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Diacerein

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OnQuality Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            OnQuality Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OQL036

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OnQuality Announces FDA Clearance of IND Application for OQL036

                            Details : OQL036 is a novel topical agent that locally alleviates the toxicities induced by capecitabine metabolites, and reduces the inflammation associated with capecitabine-induced hand-foot syndrome (HFS).

                            Product Name : OQL036

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2023

                            Lead Product(s) : OQL036

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            InnoCare Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICP-488

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

                            Details : ICP-488 is a potent and selective TYK2 allosteric inhibitor that, by binding the JH2 domain, blocks the signal transduction of IL-23, IL-12, type 1 IFN and another inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and infla...

                            Product Name : ICP-488

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2022

                            Lead Product(s) : ICP-488

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lynk Pharmaceuticals

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Lynk Pharmaceuticals

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LNK01004

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

                            Details : LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple cytokine-induced signaling pathways in vitro and in vivo. LNK01004 is tissue-restricted inhibitor that can potentially prevent safety issues caused by systemic drug exposure.

                            Product Name : LNK01004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : LNK01004

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kintor Pharmaceutical

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia Patients

                            Details : KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy...

                            Product Name : KX-826

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 24, 2021

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kintor Pharmaceutical

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT20029

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Ac...

                            Details : The trial is a randomized, double-blind, vehicle-controlled, parallel-group, dose-escalationstudy in subjects to evaluate the safety, tolerability, and pharmacokinetics of GT20029 following topical single and multiple ascending dose administration.

                            Product Name : GT20029

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 13, 2021

                            Lead Product(s) : GT20029

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth